Last reviewed · How we verify
NCT04618510: SLIMS
SEED-LVPEI Myopia Study
NA trial testing SEED 1-dayPure EDOF soft contact lens in Myopia in 108 participants. Status unknown.
30 August 2021
Quick facts
| Lead sponsor | L.V. Prasad Eye Institute |
|---|---|
| Phase | NA |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | single |
| Primary purpose | treatment |
| Enrollment | 108 |
| Start date | 11 December 2020 |
| Primary completion | 30 August 2021 |
| Estimated completion | 30 August 2022 |
| Sites | 1 location across India |
Drugs / interventions tested
- SEED 1-dayPure EDOF soft contact lens
- Single Vision Spectacles
Conditions studied
- Myopia — all drugs for Myopia →
Sponsor
L.V. Prasad Eye Institute
Who can join
Adults 7 to 15, any sex, with Myopia. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This randomized clinical trial study aims to investigate the efficacy of novel SEED's EDOF based mid-lens design in controlling the myopia progression in Indian children with these specific objectives: 1. To investigate the efficacy of SEED's 1-day pure extended depth of focus lenses controlling myopia progression in Indian children through a one-year randomized clinical study. 2. To investigate the role of SEED's 1-day pure extended depth of focus lenses in altering peripheral refraction of the eye to control myopia progression. 3. To determine if there is any specific cohort that shows better efficacy in myopia control with 1-day pure extended depth of focus lenses based on central and peripheral optics (degree of myopia and optical parameters). 4. To investigate the qualitative assessment of comfort and visual experience with the SEED's EDOF contact lenses through the questionnaire method.
Publications & conference data
2 peer-reviewed publications reference this trial (live from Europe PMC):
-
Interventions for myopia control in children: a living systematic review and network meta-analysis.
Lawrenson JG, Shah R, Huntjens B, Downie LE, et al · · 2023 · cited 117× · PMID 36809645 · DOI 10.1002/14651858.cd014758.pub2 -
Randomised clinical trial of extended depth of focus lenses for controlling myopia progression: Outcomes from SEED LVPEI Indian Myopia Study.
Manoharan MK, Verkicharla PK. · · 2024 · cited 8× · PMID 38604622 · DOI 10.1136/bjo-2023-323651
Verify or expand the search:
- PubMed search for NCT04618510
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Myopia
Currently open trials in the same condition.
- NCT07284966 — Comfort and Vision With TOTAL30 Multifocal Lenses · recruiting
- NCT07078799 — Wavefront-guided LASIK Surgery Compared to Ray Tracing-Guided LASIK Surgery · NA · recruiting
- NCT07585877 — Effect of Branched-Chain Amino Acid Supplementation on Myopia Progression · NA · active not recruiting
- NCT07354945 — An Evaluation of Myopia Control Lenses on Wearing Experience in Myopic Children · NA · recruiting
- NCT07229365 — Children's Viewing Behavior · NA · recruiting
Other L.V. Prasad Eye Institute trials
Trials by the same sponsor.
- NCT04843839 — CHED - Congenital Hereditary Endothelial Dystrophy: New Paradigm Shift in Therapy Using Topical Eye Drops · Phase 2 · unknown
- NCT06613919 — Six-months Versus Nine-months ATT for Ocular TB · Phase 4 · completed
- NCT03548805 — Ologen® Collagen Matrix Versus Mitomycin-C in Patients With Juvenile-onset Open Angle Glaucoma · NA · completed
- NCT03541551 — Ologen® Collagen Matrix in Patients With Primary Congenital Glaucoma Undergoing Trabeculectomy · NA · completed
- NCT03230058 — Combination Treatment of 5% Natamycin and 1% Voriconazole in Fungal Keratitis · Phase 2, PHASE3 · unknown
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04618510 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by L.V. Prasad Eye Institute
- Last refreshed: 24 September 2021
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04618510.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing